MX2008008453A - Adenovirus adipogenicos como biomarcadores para enfermedades. - Google Patents

Adenovirus adipogenicos como biomarcadores para enfermedades.

Info

Publication number
MX2008008453A
MX2008008453A MX2008008453A MX2008008453A MX2008008453A MX 2008008453 A MX2008008453 A MX 2008008453A MX 2008008453 A MX2008008453 A MX 2008008453A MX 2008008453 A MX2008008453 A MX 2008008453A MX 2008008453 A MX2008008453 A MX 2008008453A
Authority
MX
Mexico
Prior art keywords
adenovirus
adipogenic
cancer
subject
sample
Prior art date
Application number
MX2008008453A
Other languages
English (en)
Spanish (es)
Inventor
Richard L Atkinson
Original Assignee
Obetech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obetech Llc filed Critical Obetech Llc
Publication of MX2008008453A publication Critical patent/MX2008008453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
MX2008008453A 2005-12-27 2006-12-27 Adenovirus adipogenicos como biomarcadores para enfermedades. MX2008008453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75340205P 2005-12-27 2005-12-27
PCT/US2006/062632 WO2007120362A2 (en) 2005-12-27 2006-12-27 Adipogenic adenoviruses as a biomarker for disease

Publications (1)

Publication Number Publication Date
MX2008008453A true MX2008008453A (es) 2008-11-28

Family

ID=38610014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008008453A MX2008008453A (es) 2005-12-27 2006-12-27 Adenovirus adipogenicos como biomarcadores para enfermedades.

Country Status (11)

Country Link
US (5) US7442511B2 (enExample)
EP (2) EP2390372A1 (enExample)
JP (1) JP2009521707A (enExample)
KR (1) KR20080114683A (enExample)
CN (1) CN101389768B (enExample)
AU (1) AU2006342053A1 (enExample)
BR (1) BRPI0620755A2 (enExample)
CA (1) CA2635269A1 (enExample)
MX (1) MX2008008453A (enExample)
RU (1) RU2008130893A (enExample)
WO (1) WO2007120362A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507418B2 (en) * 2005-09-09 2009-03-24 Obetech, Llc Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
WO2007120362A2 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
JP2009156254A (ja) * 2007-12-05 2009-07-16 Ibiden Co Ltd 排気ガス処理体の保持シール部材及び排気ガス処理装置
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
WO2010011440A2 (en) * 2008-06-16 2010-01-28 Obetech Llc Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
WO2011050299A2 (en) * 2009-10-22 2011-04-28 Obetech Llc Adenovirus infection in animals
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8585588B2 (en) 2009-11-18 2013-11-19 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2011119915A2 (en) * 2010-03-25 2011-09-29 Obetech Llc Method for detecting lipogenic adenovirus
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2590665B1 (en) * 2010-07-08 2015-09-16 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
US20130178517A1 (en) * 2010-07-09 2013-07-11 Richard L. Atkinson Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
JP2017537145A (ja) 2014-11-05 2017-12-14 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ カンピロバクター・ジェジュニに対する合成抗原コンストラクト
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
EP3861348A4 (en) * 2018-10-05 2022-07-20 Minomic International Ltd. BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
AU6884298A (en) * 1997-04-04 1998-10-30 Obetech, Llc Viral obesity methods and compositions
JP2000072800A (ja) * 1998-08-26 2000-03-07 Toagosei Co Ltd 抗アデノウイルス３７型モノクローナル抗体及びその用途
ES2472325T3 (es) * 2005-11-30 2014-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Gen y proteína del adenovirus 36 E4 orf 1 y sus usos
WO2007120362A2 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease

Also Published As

Publication number Publication date
AU2006342053A1 (en) 2007-10-25
KR20080114683A (ko) 2008-12-31
US20130323273A1 (en) 2013-12-05
US7910310B2 (en) 2011-03-22
US20110189235A1 (en) 2011-08-04
EP2390372A1 (en) 2011-11-30
BRPI0620755A2 (pt) 2011-11-22
US20090087455A1 (en) 2009-04-02
US20090087833A1 (en) 2009-04-02
WO2007120362A3 (en) 2008-08-14
CA2635269A1 (en) 2007-10-25
EP1977009A2 (en) 2008-10-08
US20070218081A1 (en) 2007-09-20
WO2007120362A2 (en) 2007-10-25
EP1977009B1 (en) 2016-08-17
US7442511B2 (en) 2008-10-28
RU2008130893A (ru) 2010-02-10
CN101389768A (zh) 2009-03-18
US7745110B2 (en) 2010-06-29
JP2009521707A (ja) 2009-06-04
EP1977009A4 (en) 2009-06-03
CN101389768B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
US7910310B2 (en) Adipogenic adenoviruses as a biomarker for disease
USRE42129E1 (en) Viral obesity methods and compositions
EP0217919A1 (en) DNA SEQUENCES AND PEPTIDES SPECIFIC TO PAPILLOMA VIRUS.
CN101852804A (zh) Gdf15蛋白的抗体的新用途
CN111518909B (zh) Mettl2基因在制备检测结直肠癌氟尿嘧啶类药物治疗敏感性的试剂盒中的应用
CN111607571B (zh) 一种特异性激活免疫共刺激通路的复制型溶瘤腺病毒及其制备方法和应用
US20090220946A1 (en) Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
WO2010011440A2 (en) Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
CN119220503A (zh) Bag6基因在调节流感病毒复制中的应用
Egg et al. The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study
EP2225366A1 (en) Use of enterovirus for diagnostics, treatment and prevention of disease
KR100785397B1 (ko) 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
CN108754030A (zh) 一种人ki多瘤病毒的荧光定量pcr引物和探针及其应用
US20120244187A1 (en) Adenovirus Infection In Animals
KR102080996B1 (ko) 암세포 특이적 아데노바이러스
CN120629571A (zh) Lepr基因或蛋白作为靶标在制备胆管细胞癌治疗产品中的用途
ES2528738T3 (es) Método para potenciar la eficacia de una preparación de un anticuerpo monoclonal
CN117431247A (zh) 一种靶向igf-1r的核酸适配体及其应用
CN121588147A (zh) Tpra1在溶瘤病毒抗肿瘤效应中的应用
CN114588153A (zh) 小分子抑制剂ml385在抑制肿瘤细胞pd-l1方面的应用
CN109988839A (zh) Mindy1在宫颈病变疾病中的应用

Legal Events

Date Code Title Description
FG Grant or registration